SG11202102882YA - Antigen-binding molecule comprising altered antibody variable region - Google Patents

Antigen-binding molecule comprising altered antibody variable region

Info

Publication number
SG11202102882YA
SG11202102882YA SG11202102882YA SG11202102882YA SG11202102882YA SG 11202102882Y A SG11202102882Y A SG 11202102882YA SG 11202102882Y A SG11202102882Y A SG 11202102882YA SG 11202102882Y A SG11202102882Y A SG 11202102882YA SG 11202102882Y A SG11202102882Y A SG 11202102882YA
Authority
SG
Singapore
Prior art keywords
antigen
variable region
binding molecule
antibody variable
altered antibody
Prior art date
Application number
SG11202102882YA
Inventor
Tomoyuki Igawa
Shu Feng
Shu Wen Samantha Ho
Hirotake Shiraiwa
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of SG11202102882YA publication Critical patent/SG11202102882YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11202102882YA 2018-09-28 2019-09-27 Antigen-binding molecule comprising altered antibody variable region SG11202102882YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018185120 2018-09-28
PCT/JP2019/038087 WO2020067399A1 (en) 2018-09-28 2019-09-27 Antigen-binding molecule comprising altered antibody variable region

Publications (1)

Publication Number Publication Date
SG11202102882YA true SG11202102882YA (en) 2021-04-29

Family

ID=69950667

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202102882YA SG11202102882YA (en) 2018-09-28 2019-09-27 Antigen-binding molecule comprising altered antibody variable region

Country Status (11)

Country Link
US (1) US20220112296A1 (en)
EP (1) EP3856789A4 (en)
JP (2) JP2022501325A (en)
KR (1) KR20210068061A (en)
CN (1) CN113260634A (en)
AU (1) AU2019347408A1 (en)
BR (1) BR112021005472A2 (en)
CA (1) CA3113594A1 (en)
MX (1) MX2021003609A (en)
SG (1) SG11202102882YA (en)
WO (1) WO2020067399A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015068847A1 (en) 2013-11-11 2015-05-14 中外製薬株式会社 Antigen-binding molecule containing modified antibody variable region
EP3219724A4 (en) 2014-11-11 2018-09-26 Chugai Seiyaku Kabushiki Kaisha Library of antigen-binding molecules including modified antibody variable region
WO2019111871A1 (en) 2017-12-05 2019-06-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule comprising altered antibody variable region binding cd3 and cd137
JP2021175391A (en) * 2020-03-31 2021-11-04 中外製薬株式会社 Immune-activating multispecific antigen binding molecule and use thereof
MX2022012092A (en) * 2020-03-31 2022-10-13 Chugai Pharmaceutical Co Ltd Claudin-6 targeting multispecific antigen-binding molecules and uses thereof.
IL296802A (en) * 2020-03-31 2022-11-01 Chugai Pharmaceutical Co Ltd Method for producing multispecific antigen-binding molecules
CA3173587A1 (en) 2020-03-31 2021-10-07 Chugai Seiyaku Kabushiki-Kaisha Dll3-targeting multispecific antigen-binding molecules and uses thereof
JP7470760B2 (en) * 2021-09-29 2024-04-18 中外製薬株式会社 Cytotoxicity-inducing therapeutic agent for use in the treatment of cancer
JP7557922B2 (en) 2021-09-29 2024-09-30 中外製薬株式会社 Uses of DLL3-targeting multispecific antigen-binding molecules
WO2023053282A1 (en) * 2021-09-29 2023-04-06 中外製薬株式会社 Cytotoxicity-inducing therapeutic agent for use in treatment of cancer
WO2023053272A1 (en) * 2021-09-29 2023-04-06 Chugai Seiyaku Kabushiki Kaisha Uses of dll3-targeting multispecific antigen-binding molecules
WO2023154533A2 (en) * 2022-02-14 2023-08-17 Twist Bioscience Corporation Combinatorial dna assembly for multispecific antibodies
WO2024179567A1 (en) * 2023-03-01 2024-09-06 江苏恒瑞医药股份有限公司 Fap/4-1bb/cd40 binding molecule and medicinal use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1141024B1 (en) 1999-01-15 2018-08-08 Genentech, Inc. POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION
BRPI0510674A (en) 2004-07-15 2007-12-26 Xencor Inc optimized fc variants
PL2334705T3 (en) * 2008-09-26 2017-06-30 Ucb Biopharma Sprl Biological products
SG10201407908VA (en) * 2008-12-19 2015-01-29 Macrogenics Inc Covalent diabodies and uses thereof
US9518132B2 (en) * 2010-11-09 2016-12-13 Altimab Therapeutics, Inc. Protein complexes for antigen binding and methods of use
BR112013012213A2 (en) * 2010-11-17 2020-09-01 Chugai Seiyaku Kabushiki Kaisha multi-specific antigen-binding molecules having an alternative function to the function of factors viii, ix ex of blood coagulation, and bispecific antibody, their uses in the prevention or treatment of hemorrhage, nucleic acid, vector, cell, method to produce the aforementioned binding molecules, pharmaceutical composition and kit
WO2014116846A2 (en) * 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
WO2015068847A1 (en) * 2013-11-11 2015-05-14 中外製薬株式会社 Antigen-binding molecule containing modified antibody variable region
SG11201606850QA (en) * 2014-03-12 2016-09-29 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
WO2015146438A1 (en) * 2014-03-26 2015-10-01 国立大学法人東北大学 Bispecific antibody targeting human epidermal growth factor receptor
SG11201607434WA (en) * 2014-04-07 2016-10-28 Chugai Pharmaceutical Co Ltd Immunoactivating antigen-binding molecule
CN107001482B (en) * 2014-12-03 2021-06-15 豪夫迈·罗氏有限公司 Multispecific antibodies
EP3305322A4 (en) * 2015-06-05 2018-12-26 Chugai Seiyaku Kabushiki Kaisha Combined use of immune activators
IL258405B (en) * 2015-10-23 2022-09-01 Eureka Therapeutics Inc Antibody/t-cell receptor chimeric constructs and uses thereof
RU2750721C2 (en) * 2017-03-10 2021-07-01 Ф. Хоффманн-Ля Рош Аг Method for the production of multi-specific antibodies
WO2019111871A1 (en) * 2017-12-05 2019-06-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule comprising altered antibody variable region binding cd3 and cd137
MX2021000827A (en) * 2018-08-03 2021-03-25 Chugai Pharmaceutical Co Ltd Antigen-binding molecule containing two antigen-binding domains that are linked to each other.

Also Published As

Publication number Publication date
AU2019347408A1 (en) 2021-04-15
CA3113594A1 (en) 2020-04-02
JP2022501325A (en) 2022-01-06
EP3856789A4 (en) 2022-08-17
KR20210068061A (en) 2021-06-08
US20220112296A1 (en) 2022-04-14
JP2024105621A (en) 2024-08-06
CN113260634A (en) 2021-08-13
EP3856789A1 (en) 2021-08-04
MX2021003609A (en) 2021-05-28
WO2020067399A1 (en) 2020-04-02
BR112021005472A2 (en) 2021-06-15

Similar Documents

Publication Publication Date Title
SG11202102882YA (en) Antigen-binding molecule comprising altered antibody variable region
IL279321A (en) Anti-sirpα antibody
IL283812A (en) Humanized anti-human-pd-1 antibody
SG11202001368SA (en) Antigen-binding proteins tatrgeting shared antigens
SG11202009361PA (en) Her3 antigen-binding molecules
IL263936A (en) Humanized monoclonal antibodies that target ve-ptp (hptp-beta)
IL282756A (en) Humanized anti-sirpα antibodies
ZA202004908B (en) Bispecific antibody
SG11202007735TA (en) Anti-her2 antibodies
EP3590964A4 (en) Improved anti-vegfr-2 monoclonal antibody
ZA202205226B (en) Ri-labeled humanized antibody
EP3567053A4 (en) Anti-claudin-2 monoclonal antibody
ZA202101177B (en) Anti-btla antibody
GB201811403D0 (en) Antibody molecules
IL279823A (en) Humanized antibodies against psma
GB201811368D0 (en) Antibody
IL279355A (en) Anti-steap1 antigen-binding protein
GB201817172D0 (en) Antibody
EP3753956A4 (en) Antigen-binding molecule and combination
IL292799A (en) Anti-siglec-9 antibody molecules
EP3877420A4 (en) Her2 s310f specific antigen-binding molecules
GB201911211D0 (en) Monoclonal antibodies against ambra-1
EP3690051A4 (en) Anti-ckap4 monoclonal antibody
EP3710048A4 (en) Humanized 2c7 monoclonal antibody directed against aneisseria gonorrhoeae
EP3656791A4 (en) Anti-human ccr1 monoclonal antibody